Analysis of drug resistant mutations among AIDS patients with integrase inhibitors in Hunan province in 2020
10.3760/cma.j.cn112866-20210716-00128
- VernacularTitle:湖南省2020年整合酶抑制剂治疗的艾滋病患者HIV耐药突变分析
- Author:
Mengran LIANG
1
;
Xiaobai ZOU
;
Jianmei HE
;
Xi CHEN
Author Information
1. 南华大学公共卫生学院，衡阳 421001
- Keywords:
Human immunodeficiency virus (HIV);
Acquired immunodeficiency syndrome (AIDS);
Integrase inhibitors;
Drug resistance mutation;
Antiretroviral therapy (ART
- From:
Chinese Journal of Experimental and Clinical Virology
2022;36(1):92-96
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To provide data support for acquired immunodeficiency syndrome (AIDS) clinical treatment by evaluating the antiviral therapy effect of integrase inhibitors (INIs) and analyzing the drug resistant mutations.Methods:Patients who exposed to INIs more than 1 year were analyzed retrospectively. Virus suppression failure subjects(viral load ≥1 000 copies/ml) were sequenced for drug resistance analysis.Results:Of 408 patients, 12 cases(2.9%) were virologic failure, 8 cases had drug resistance mutations. The proportion of drug resistance was 2.0%(8/408). Among them, only 1 case(0.2%, 1/408) was resistant to INIs with associated mutations: T66I, G118R and E138K; 7 cases(1.7%, 7/408) were resistant to nucleoside reverse transcriptase inhibitors(NRTIs) with major mutations: M184V/I, D67N for NRTIs; 5 cases(1.2%, 5/408) were resistant to non-nucleoside reverse transcriptase inhibitors(NNRTIs) with major mutation: K103N; 1 case(0.2%, 1/408) was resistant to protein inhibitors (PIs), and associated mutations was I50L.1 case was resistant simultaneously to INIs, NRTIs and NNRTIs, Dual-class mutations were observed in 4 cases(3 cases to NRTIs and NNRTIs, 1 case to PIs and NNRTIs).Conclusions:The study result showed that the drug resistance rate of INIs was low in Hunan province, however, the INIs drug resistance surveillance was necessary.
